ArticleDiscover oncology2025
Mendelian randomization and single-cell analysis reveal novel genetic risk factors and cellular heterogeneity in glioblastoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundGlioblastoma is the most aggressive primary brain tumor with limited therapeutic options and poor prognosis. Understanding the genetic determinants and cellular complexity of glioblastoma is crucial for developing novel therapeutic strategies.
methodsWe conducted a comprehensive Mendelian randomization (MR) analysis to investigate causal relationships between genetic exposures and glioblastoma risk, employing multiple MR methods including MR Egger, weighted median, inverse variance weighted, simple mode, and weighted mode approaches. Single-cell RNA sequencing was performed to characterize cellular heterogeneity within the glioblastoma microenvironment. Extensive sensitivity analyses including funnel plots and leave-one-out analyses were conducted to ensure robust causal inference. RT-PCR validation was conducted using BV2 glioma cell line compared to normal brain tissue controls. Integration analysis linked genetic risk factors to cellular expression patterns and biological pathways.
resultsThe Mendelian randomization analysis identified several genes with robust causal relationships to glioblastoma risk. Protective associations were observed for TIMP3 (OR = 0.675, 95% CI: 0.473-0.965, p = 0.031), TREM1 (OR = 0.631, 95% CI: 0.411-0.968, p = 0.035), FLRT3 (OR = 0.661, 95% CI: 0.512-0.853, p = 0.001), and IL12B (OR = 0.644, 95% CI: 0.448-0.925, p = 0.017). Conversely, risk-increasing associations were identified for TALDO1 (OR = 12.433, 95% CI: 1.808-85.507, p = 0.010) and PDCD6 (OR = 4.532, 95% CI: 1.429-14.368, p = 0.010). RT-PCR validation confirmed significant downregulation of protective genes in BV2 glioma cells: TIMP3 (2.48-fold decrease, p = 0.031), TREM1 (2.74-fold decrease, p = 0.035), FLRT3 (2.91-fold decrease, p = 0.001), and IL12B (2.33-fold decrease, p = 0.017). Single-cell analysis revealed distinct cellular populations with cell-type-specific expression patterns of identified risk genes.
conclusionsThis study provides robust evidence for novel genetic risk factors in glioblastoma development and reveals the complex cellular landscape of the tumor microenvironment. The identified protective and risk genes offer potential targets for therapeutic intervention and biomarker development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.